advertisement
Abstract #10816 Published in IGR 6-2
Efficacy of Bimatoprost 0.03 Percent in Untreated Glaucoma and Ocular Hypertension Patients: Results from a Large Community-Based Clinical Trial
Quinones R; Severin T; Mundorf TJournal of Ocular Pharmacology and Therapeutics 2004; 20: 115-122
PURPOSE: To evaluate the intraocular pressure- (IOP-) lowering efficacy of bimatoprost 0.03% (Lumigan,R Allergan, Inc.) monotherapy in the treatment of patients with glaucoma or ocular hypertension not currently using ocular hypotensives. METHODS: Open-label, community-based, multicenter evaluation. Patients (n = 6767) who, according to their physicians, required IOP lowering were prescribed bimatoprost for 2 months. Subgroup alyses of the results, stratified by treatment history and use of concomitant medications, were performed. This report focuses on the subgroup of patients that was not being treated with antiglaucoma medications at baseline (n = 1946, 29%). All of these patients were placed on bimatoprost monotherapy. RESULTS: The mean IOP at the untreated baseline was 23.8 mmHg. Bimatoprost provided a mean IOP reduction of 7.5 mmHg (30%, p < 0.001) from baseline after 2 months of monotherapy. Further, bimatoprost allowed patients to achieve low target pressures. For example, 41.5% of patients achieved target IOPs of
Dr. R. Quinones, Arbor Center For Eye Care 2640, 183rd Street, Homewood, IL 60430
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
